PharmNovaTechBridge
CEE Health-Science Venture Builder & Commercial Accelerator
We co-build, develop, and commercially accelerate health-science ventures in Central & Eastern Europe. Pharma, Biotech, and One Health – from early stage to exit.
Building the Next Generation of Health-Science Ventures in CEE
PharmNovaTechBridge is an active venture builder across pharma, biotech, and One Health in Central & Eastern Europe. We co-create, invest, and commercially develop health-science companies from early stage to exit.
CEE produces world-class science. We turn it into commercially successful, investable companies.
1
Pharma
6 ONGOING PROJECTS
We scout, broker, and selectively develop pharmaceutical assets — from niche molecules to orphan drugs — bridging early innovation with global pharma markets.
2
Veterinary
5 ONGOING PROJECTS
Supporting animal health with innovative therapies, diagnostics, and supplements. We enable veterinary-focused companies to expand across Europe and beyond.
3
CBRN
3 ONGOING RESEARCH PROJECTS
Partnering with defense and government stakeholders to supply pharmaceuticals, medtech, and countermeasure solutions tailored to operational needs.
1
Pharma & Biotech
We build and commercially develop pharmaceutical and biotech ventures – specialty molecules, diagnostics, drug delivery platforms, and novel therapeutics. We identify assets with a credible licensing or acquisition path and actively drive them toward it.
2
One Health – Human & Veterinary
One of the very few venture builders in Europe operating across both human and animal health. We build companies whose products address health across species.
3
Commercial Acceleration
We partner with established CEE health-science companies that have hit a commercial ceiling. We open Western markets, structure licensing and partnership deals, and drive active BD – not reports, not advice.
4
Venture Creation
Where we see a genuine gap, we originate and build ventures from scratch forming teams, securing non-dilutive funding, and developing companies toward a strategic exit or acquisition.
5
Asset Evaluation & Scouting
We source, screen, and scientifically evaluate health-science investment opportunities across CEE on behalf of VC funds, private equity, and family offices. Our team combines pharmacology-level scientific due diligence with hands-on commercial assessment – giving investors a trusted regional partner who knows the terrain before they commit capital.
CEE health science has exceptional talent, real innovation, and genuine commercial potential. What it has lacked is the right partner to take it to market.
We are scientists and operators who build, invest in, and commercially develop health-science companies across the region. We take equity, we share the risk, and we stay until the outcome.
That is what makes us different.
Kristian Lorenc
CEO and Co-Founder of PNTB
Kamil Kuca
CSO and Co-founder of PNTB
